ONCOS-102

AXP000035.1 · Oncolytic virus

Platform
adenovirus (Ad5/3 chimera, Delta-24, E3 gp19k/6.7k replaced by GM-CSF)
Originator
Oncos Therapeutics
Sponsor
Targovax

Names

NameTypeSource
ONCOS-102preferred name, codecurator, ncit
Ad5/3-D24-GMCSFsynonympaper
CGTG-102former codencit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5/3 chimera
Replication
conditionally replicating
Modifications
24-bp E1A CR2 deletion; Ad3 fiber knob; GM-CSF in place of E3 gp19k/6.7k
Transgenes
CSF2
Route
intratumoral, intraperitoneal
Source
evidence

Cross-references

NCI Thesaurus
C98287

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05561491A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma PatientsWithdrawnPhase 22024-012027-060Melanoma
NCT03514836A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate CancerTerminatedPhase 1/22018-05-232021-01-255Castration-resistant Prostate Cancer
NCT02963831A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal MalignanciesCompletedPhase 1/22017-09-072022-06-2567Appendiceal Cancer; Colorectal Cancer; Ovarian Cancer
NCT03003676A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) BlockadeCompletedPhase 12016-122020-0721Advanced or Unresectable Melanoma Progressing After PD1 Blockade
NCT02879669A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural MesotheliomaUnknownPhase 1/22016-062020-0531To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
NCT01598129ONCOS-102 (Previously CGTG-102) for Therapy of Advanced CancersCompletedPhase 12012-042013-1012Malignant Solid Tumour
NCT01437280GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced CancersWithdrawnPhase 10Solid Tumors; Tumors

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 37661097ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.Journal for immunotherapy of cancer2023name in title: ONCOS-102
PMID 30713786Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.Oncoimmunology2019cited by trial NCT03003676
PMID 26981247Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.Journal for immunotherapy of cancer2016cited by trial NCT01598129
PMID 23493351Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.Clinical cancer research : an official journal of the American Association for Cancer Research2013name in abstract: Ad5/3-D24-GMCSF
PMID 20664527Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Molecular therapy : the journal of the American Society of Gene Therapy2010name in abstract: Ad5/3-D24-GMCSF

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42397418EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.Cancer immunology, immunotherapy : CII2026name in abstract: ONCOS-102
PMID 39941870A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials.Cancers2025name in abstract: ONCOS-102
PMID 38454393Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy.Journal of translational medicine2024name in abstract: ONCOS-102
PMID 36112545Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research2023name in title: ONCOS-102
PMID 36269283ONCOS-102: A Step Forward or Sideways?Clinical cancer research : an official journal of the American Association for Cancer Research2023name in title: ONCOS-102
PMID 34277838Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine2021name in abstract: ONCOS-102
PMID 31944306Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor.Journal of medical virology2020name in abstract: ONCOS-102
PMID 31081549Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.Journal of medical virology2019name in abstract: ONCOS-102
PMID 29797583Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.Journal of medical virology2018name in title: ONCOS-102
PMID 28796812Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.PloS one2017name in title: ONCOS-102
PMID 27057453Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Oncoimmunology2016name in abstract: Ad5/3-D24-GMCSF
PMID 27287512Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.International journal of cancer2016name in title: Ad5/3-D24-GMCSF
PMID 28051835Mesothelioma and interferon-γ-dependent chemokine IP-10.La Clinica terapeutica2016name in abstract: ONCOS-102
PMID 24975392Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.International journal of cancer2015name in abstract: Ad5/3-D24-GMCSF
PMID 25821063Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.International journal of cancer2015name in abstract: Ad5/3-D24-GMCSF
PMID 26140248Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.Oncoimmunology2015name in title: ONCOS-102
PMID 24374597Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.International journal of cancer2014name in abstract: Ad5/3-D24-GMCSF
PMID 25941579Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.Oncoimmunology2014name in title: ONCOS-102
PMID 20582867American Society of Gene & Cell Therapy--13th Annual Meeting.IDrugs : the investigational drugs journal2010name in abstract: CGTG-102

NIH grants

ProjectTitleOrganisationPIYearsLinked by
K00CA274650Defining tumor and blood-based immunogenomic signatures predicting response to immunotherapy in ovarian cancerICAHN SCHOOL OF MEDICINE AT MOUNT SINAIMONSON, KELSEY R2025–2026name in abstract: ONCOS-102
R01CA269382POTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATIONICAHN SCHOOL OF MEDICINE AT MOUNT SINAIZAMARIN, DMITRIY2023–2026name in abstract: ONCOS-102

Notes

Development code CGTG-102; the same construct was given to ATAP patients in Finland as Ad5/3-D24-GMCSF before Oncos Therapeutics was formed. Oncos Therapeutics merged with Targovax in 2015. Targovax deprioritised its oncolytic adenovirus programme around 2022-2023; current status not confirmed from a primary source.

How to cite

ONCOS-102 (AXP000035.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000035.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.